Molecular bases of the poor response of liver cancer to chemotherapy
| Autor: | Ana I. Santos-Llamas, Jose J.G. Marin, Maitane Asensio, Carolina Armengol, Maria A. Serrano, Oscar Briz, Marta R. Romero, Rocio I.R. Macias, Thomas Efferth, Luis M. Osorio-Padilla, Elisa Herraez, Elisa Lozano, Silvia Di Giacomo |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Hepatoblastoma Carcinoma Hepatocellular Genetic enhancement medicine.medical_treatment Cholangiocarcinoma 03 medical and health sciences 0302 clinical medicine Humans Medicine cholangiocarcinoma hepatoblastoma hepatocellular carcinoma multidrug resistance targeted therapies hepatology gastroenterology Chemotherapy Hepatology business.industry Liver Neoplasms Gastroenterology medicine.disease Phenotype Resistome 030104 developmental biology Drug Resistance Neoplasm 030220 oncology & carcinogenesis Hepatocellular carcinoma Cancer cell Cancer research business Liver cancer |
| Zdroj: | Clinics and Research in Hepatology and Gastroenterology. 42:182-192 |
| ISSN: | 2210-7401 |
| DOI: | 10.1016/j.clinre.2017.12.006 |
| Popis: | Summary A characteristic shared by most frequent types of primary liver cancer, i.e., hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) in adults, and in a lesser extent hepatoblastoma (HB) mainly in children, is their high refractoriness to chemotherapy. This is the result of synergic interactions among complex and diverse mechanisms of chemoresistance (MOC) in which more than 100 genes are involved. Pharmacological treatment, although it can be initially effective, frequently stimulates the expression of MOC genes, which results in the relapse of the tumor, usually with a more aggressive and less chemosensitive phenotype. Identification of the MOC genetic signature accounting for the “resistome” present at each moment of tumor life would prevent the administration of chemotherapeutic regimens without chance of success but still with noxious side effects for the patient. Moreover, a better description of cancer cells strength is required to develop novel strategies based on pharmacological, cellular or gene therapy to overcome liver cancer chemoresistance. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect